In various immunologically “cold” tumor models, including pancreatic adenocarcinoma and glioblastoma, agonistic CD40 antibodies (aCD40) have successfully activated cDC1s, improved T cell priming, and enhanced anti-tumor immunity21,41. Here, CD40 is linked to pancreatic adenocarcinoma.